ArticleUrologic oncology2013
Low-dose diethylstilbestrol for the treatment of advanced prostate cancer.
Article in Urologic oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 33 citations in OpenAlex.
- The Influence of Environmental Exposure to Xenoestrogens on the Risk of Cancer Development.International journal of molecular sciences · 2024Review
- Estrogenic endocrine disruptor exposure directly impacts erectile function.Communications biology · 2024Article
- Review
- 2-Trifluoromethylthiazole-5-carboxamides: Analogues of a Stilbene-Based Anti-HIV Agent that Impact HIV mRNA Processing.ACS medicinal chemistry letters · 2021Article
- Supplemental estrogen and caloric restriction reduce obesity-induced periprostatic white adipose inflammation in mice.Carcinogenesis · 2019Article
- Estrogens and prostate cancer.Prostate cancer and prostatic diseases · 2019Review
- Favourable response of serum prostate-specific antigen to conjugated oestrogen in castrate-resistant prostate cancer in Jamaica.Ecancermedicalscience · 2018Article
- Estrogen Exhibits a Biphasic Effect on Prostate Tumor Growth through the Estrogen Receptor β-KLF5 Pathway.Molecular and cellular biology · 2016Article
- Environmental endocrine disruptors: Effects on the human male reproductive system.Reviews in endocrine & metabolic disorders · 2015Review
- Direct estradiol and diethylstilbestrol actions on early- versus late-stage prostate cancer cells.The Prostate · 2014Article
- Review
- Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.British journal of cancer · 2013Article
- Overview of the latest treatments for castration-resistant prostate cancer.Nature reviews. Urology · 2013Review
- The male mammary gland: a target for the xenoestrogen bisphenol A.Reproductive toxicology (Elmsford, N.Y.) · 2013Article
- Optimal management of recurrent prostate cancer in older patients.Drugs & aging · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
objectivesThe purpose of this study was to assess the efficacy and safety of low-dose (1 mg) daily diethylstilbestrol (DES) for the treatment of castrate-resistant prostate cancer (CRPC). MATERIALS AND
methodsA retrospective chart review was performed on patients treated with low-dose DES who had CRPC despite anti-androgen withdrawal. The study population consists of 63 patients treated in the pre- and post-chemotherapy settings based on a database review; 58 had sufficient data for efficacy, all were analyzed for safety.
resultsA PSA decrease of ≥50% was observed in 19 of 49 pre-chemotherapy patients (39%) with a median time to progression (TTP) of 30 weeks (95% CI, 21.9, 68.7). A PSA decrease of <50% was seen in another 16 patients (33%) with a median TTP of 16.4 weeks (95% CI, 13.0, 37.6). Fourteen patients (29%) had progressive disease by PSA testing; their median TTP was 6.9 weeks (95% CI, 5.6, 12.9). Thromboembolic events included 2 patients with DVTs and 1 patient who developed primary fibrinolysis syndrome. Additional adverse events included gynecomastia in 37 of 63 patients (59%). Secondary observations included PSA responses in 3 of 9 patients treated with DES after chemotherapy progression and a high rate of PSA responses in patients re-treated with DES after a drug holiday.
conclusionsLow-dose DES is safe and effective in a modern cohort of men with CRPC despite anti-androgen treatment. Its potential role in the post-chemotherapy setting and the suggestion of efficacy on re-challenge merits additional consideration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.